Group 1 - Vanke A's largest shareholder, Shenzhen Metro Group, plans to provide a loan of up to 1.55 billion yuan to repay the company's bonds [1] - Yidelong reported a net profit of 41.77 million yuan for Q1 2025, a year-on-year increase of 34.19% [1] - Overseas Chinese Town A achieved a contract sales amount of 1.78 billion yuan in April, a year-on-year increase of 10% [1][2] Group 2 - Dajin Heavy Industry's subsidiary signed a contract worth approximately 1 billion yuan for an offshore wind power project with a European energy company [4] - Liao Port Co. announced the resignation of Chairman Wang Zhixian due to reaching retirement age [4] - China Energy Construction's application for a specific stock issuance has been approved by the Shanghai Stock Exchange [6] Group 3 - Xinhua Insurance reported a 27% year-on-year increase in premium income from January to April, totaling 85.38 billion yuan [11] - 吉祥航空's passenger turnover increased by 6.34% in April, with a seat occupancy rate of 86.16% [13] - New City Holdings reported a contract sales amount of approximately 1.76 billion yuan in April, a year-on-year decrease of 52.46% [28] Group 4 - Three Yuan Bio announced a preliminary ruling of a 3.49% countervailing duty on its products in the U.S. [23] - Shanghai Pharmaceutical's product, Wengjing Decoction Granules, has been approved for production [20] - A strategic cooperation agreement was signed between *ST Dali and Zhuhai Yunzhou Intelligent Technology Co., Ltd. to promote the development of intelligent unmanned equipment [22] Group 5 - The construction of the automotive lightweight forging precision processing project by Sanlian Forging has been completed [25] - The company Tianma Technology reported an output of approximately 1,480.16 tons of eel in April [18][19] - The company Victory Technology plans to invest up to 3 billion yuan for share repurchase [42]

金十数据5月13日讯，华兰股份晚间公告，公司控股股东江阴华兰机电科技有限公司、实控人（华一 敏、华国平、杨菊兰）自愿承诺：自承诺公告之日起12个月内，不以任何形式减持本股东直接和间接持 有的公司股票；承诺期内如发生资本公积转增股本、派送股票红利、配股、增发等产生的股份，亦遵守 上述承诺。 华兰股份：控股股东、实控人承诺12个月内不减持公司股份 ...

关于公司控股股东、实际控制人自愿承诺不减持公司股份的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏华兰药用新材料股份有限公司（以下简称"公司"）于近日收到了公司控股 股东江阴华兰机电科技有限公司、实际控制人（华一敏先生、华国平先生、杨菊兰女 士）出具的《关于自愿承诺不减持的承诺函》，现将具体内容公布如下： 一、本次承诺的主要内容 基于对公司未来发展前景的信心以及内在价值的认可，为支持公司持续、稳定、 健康发展，同时为增强广大投资者信心，切实维护投资者权益和资本市场的稳定，本 人/本公司自愿承诺：自本承诺公告之日起 12 个月内，不以任何形式减持本股东直接 和间接持有的公司股票；承诺期内如发生资本公积转增股本、派送股票红利、配股、 增发等产生的股份，亦遵守上述承诺。若违反上述承诺，减持股份所得的收益全部归 公司所有，并依法承担由此产生的法律责任。 证券代码：301093 证券简称：华兰股份 公告编号：2025-042 江苏华兰药用新材料股份有限公司 三、其他说明 公司董事会将监督上述相关人员严格遵守承诺。若上述相关人员未遵守相关承 诺，公司董事会将保 ...

Group 1: Company Overview and Financial Performance - The company plans to distribute a cash dividend of 2 CNY per 10 shares, totaling 25,261,788.40 CNY, based on a total share capital of 126,308,942 shares [1] - The capital reserve will be used to increase share capital by 3 shares for every 10 shares held, resulting in an increase of 37,892,682 shares, bringing the total to 164,201,624 shares [2] - The net profit attributable to shareholders for 2024 decreased by 57.96% due to factors such as fluctuations in downstream demand and increased depreciation expenses [3] Group 2: Profitability and Cost Structure - The overall gross margin for 2024 was 38.79%, down from 41.62% in the previous year, reflecting a decrease of 2.83% [5] - Increased costs were attributed to rising depreciation and amortization expenses due to ongoing investment projects and changes in product structure [5] Group 3: Future Plans and Market Strategy - The company aims to enhance its competitive edge by focusing on new product development, including components for pre-filled syringes and drug delivery systems [6] - A specialized team will be established to advance the drug aluminum cap project, aiming to create an integrated supply chain for rubber stoppers and aluminum caps [6] - The company is considering the possibility of mergers and acquisitions for external expansion, subject to legal and regulatory procedures [6]

证券代码：301093 证券简称：华兰股份 公告编号：2025-041 江苏华兰药用新材料股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： "公司""华兰股份"或"发行人"）首次公开发行前部分已发行股份。 期为 2025 年 5 月 15 日（星期四）。 一、公司首次公开发行股票和股本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意江苏华 兰 药 用 新 材 料 股 份 有 限 公 司 首 次 公 开 发 行 股 票 注 册 的 批 复 》（ 证 监 许 可 20213020 号）同意注册，公司首次公开发行人民币普通股（A 股）33,666,667 股，并于 2021 年 11 月 1 日在深圳证券交易所上市交易。公司首次公开发行后总 股本为 134,666,667 股，其中有限售条件流通股 103,765,403 股，占发行后总股 本的比例为 77.05%；无限售条件流通股 30,901,264 股，占发行后总股本的比例 为 22.95%。2022 年 5 月 10 日，公司首次公开发行网下配售限售股上市流通， ...

Core Viewpoint - The report outlines the approval and details regarding the lifting of restrictions on shares of Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. prior to its initial public offering (IPO) and the subsequent listing of these shares for trading [1][2]. Summary by Sections 1. Type of Restricted Shares - The company issued 33,666,667 shares during its IPO, with a total share capital of 134,666,667 shares post-IPO. Of these, 103,765,403 shares were subject to restrictions, representing 77.05% of the total. The current release involves 1,756,450 shares, accounting for 1.30% of the total share capital [1][2]. 2. Changes in Share Capital - Following the issuance of restricted shares, the total share capital increased to 135,786,667 shares after the granting of 1,120,000 restricted shares on March 16, 2023. The company also canceled 6,412,625 shares held in a repurchase account, leading to a total of 126,308,942 shares as of the report date [3][4]. 3. Commitments and Compliance - The controlling shareholder, Jiangyin Hualan Electromechanical Technology Co., Ltd., committed to not pledging or transferring shares for 36 months post-IPO. If the stock price falls below the IPO price for 20 consecutive trading days, the lock-up period is extended by 6 months. All commitments have been adhered to without any violations [5][6][9]. 4. Listing and Trading Arrangements - The shares will be available for trading starting May 15, 2025. A total of 37,827,846 shares will be released, which is 29.9487% of the total share capital. The release involves four shareholders, with no shares being pledged or frozen [10][12]. 5. Share Structure Post-Release - After the release of restricted shares, the structure will reflect 38,032,821 restricted shares (30.11%) and 126,103,967 unrestricted shares (99.84%). The total share capital remains at 126,308,942 shares [11][12]. 6. Sponsor's Verification Opinion - The sponsor confirms that all shareholders have complied with their lock-up commitments and that the application for the release of restricted shares meets all regulatory requirements. The information disclosed regarding the release is deemed accurate and complete [13].

证券代码：301093 证券简称：华兰股份 公告编号：2025-041 江苏华兰药用新材料股份有限公司 首次公开发行前已发行股份部分解除限售并上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、本次解除限售的股份为江苏华兰药用新材料股份有限公司（以下简称 "公司""华兰股份"或"发行人"）首次公开发行前部分已发行股份。 2、本次解除限售股东户数共计 4 户，本次限售股上市流通数量为 37,827,846 股，占公司股本总数的 29.9487%，本次解除限售的股份上市流通日 期为 2025 年 5 月 15 日（星期四）。 一、公司首次公开发行股票和股本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意江苏华 兰药用新材料股份有限公司首次公开发行股票注册的批复》（证监许可 [2021]3020 号）同意注册，公司首次公开发行人民币普通股（A 股）33,666,667 股，并于 2021 年 11 月 1 日在深圳证券交易所上市交易。公司首次公开发行后总 股本为 134,666,667 股，其中有限售条件流通股 ...

Group 1 - Baichuan Energy plans to reduce its shareholding by up to 26.82 million shares, accounting for 2% of the total share capital, due to personal investment and funding needs [1] - Jinhong Gas intends to distribute a cash dividend of 1.00 yuan per 10 shares, with the record date on May 15, 2025 [2] - Jiahe Meikang's shareholder plans to reduce its stake by up to 1% of the total share capital due to liquidity needs [2][3] Group 2 - Jiadu Technology will cancel 10.20 million repurchased shares, reducing its total share capital from 2.143 billion shares to 2.133 billion shares [4] - ILE Home's shareholder plans to reduce its stake by up to 154,250 shares, accounting for 0.4778% of the total share capital, due to funding needs [5] - Lai Yifen has fully removed related batches of its honey date dumpling products from shelves due to consumer health concerns [6][7] Group 3 - CATL's vice chairman Li Ping and spouse plan to donate 4.05 million shares to Fudan University for establishing a research fund, reducing Li Ping's shareholding from 4.58% to 4.48% [8] - Shuanghuan Transmission's shareholders completed their reduction plan, selling a total of 6.69 million shares, accounting for 0.789% of the total share capital [9] - Chengfei Integration reported no significant changes in its business operations or external environment despite stock price fluctuations [10] Group 4 - Guizhou Tire's controlling shareholder plans to increase its stake by no less than 50 million yuan and no more than 100 million yuan within six months [11] - *ST Youshu's application to revoke the delisting risk warning has been approved, and its stock will resume trading under a new name [13] - Jingwei Huikai's shareholders plan to reduce their stake by up to 3% of the total share capital due to funding needs [14] Group 5 - Hualan Biological's major shareholder plans to reduce its stake by up to 3% of the total share capital due to funding needs [15] - Huyou Pharmaceutical's shareholder plans to reduce its stake by up to 2.997% of the total share capital due to funding needs [16] - Dongpeng Holdings' shareholders plan to reduce their stake by up to 1.5% of the total share capital due to funding needs [17] Group 6 - Keleke's controlling shareholder plans to reduce its stake by up to 3% of the total share capital due to funding needs [18] - Dongfang Ocean's major shareholder plans to reduce its stake by 1% of the total share capital due to investor redemption requests [19] - Yisheng Shares reported a sales revenue of 141 million yuan from white feather chicken seedlings in April, with a year-on-year decrease of 7.28% [20] Group 7 - Qujiang Cultural Tourism's controlling shareholder's 12 million shares are set to be auctioned due to contractual disputes, representing 4.70% of the total share capital [21] - Duople's shareholder plans to reduce its stake by up to 123,800 shares, accounting for 2% of the total share capital, due to personal funding needs [22][23]

Group 1 - The major shareholder, Ruizhong Life Insurance Co., Ltd., plans to reduce its stake in Hualan Co., Ltd. by up to 3,789,267 shares, representing 3.00% of the total share capital, within a three-month period starting from June 4, 2025 [1] - The reduction will occur through centralized bidding and block trading, with a maximum of 1,263,089 shares (1.00% of total share capital) to be sold via centralized bidding and 2,526,178 shares (2.00% of total share capital) via block trading [1] - Ruizhong Life Insurance is the second-largest shareholder of Hualan Co., Ltd., holding 21,956,522 shares, which accounts for 17.38% of the company's total share capital [2] Group 2 - Hualan Co., Ltd. was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on November 1, 2021, with an initial public offering of 33,666,667 shares at a price of 58.08 yuan per share, raising a total of 1.955 billion yuan [2] - The net proceeds from the IPO amounted to 1.804 billion yuan, exceeding the original plan by 1.254 billion yuan, which was intended for automation and intelligent factory renovation, research and development center construction, and working capital [2] - The total issuance costs for Hualan Co., Ltd. were 151 million yuan, with Huatai United Securities Co., Ltd. receiving 133 million yuan as underwriting and sponsorship fees [3]